- Home
- AAMI vs BEAM Comparison
AAMI vs BEAM Comparison
Compare AAMI & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- BEAM
- Stock Information
- Founded
- AAMI 1980
- BEAM 2017
- Country
- AAMI United States
- BEAM United States
- Employees
- AAMI N/A
- BEAM N/A
- Industry
- AAMI Investment Managers
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AAMI Finance
- BEAM Health Care
- Exchange
- AAMI Nasdaq
- BEAM Nasdaq
- Market Cap
- AAMI 1.6B
- BEAM 1.7B
- IPO Year
- AAMI N/A
- BEAM 2020
- Fundamental
- Price
- AAMI $48.34
- BEAM $22.45
- Analyst Decision
- AAMI Hold
- BEAM Strong Buy
- Analyst Count
- AAMI 3
- BEAM 10
- Target Price
- AAMI $35.33
- BEAM $49.78
- AVG Volume (30 Days)
- AAMI 384.1K
- BEAM 2.9M
- Earning Date
- AAMI 10-30-2025
- BEAM 11-04-2025
- Dividend Yield
- AAMI 0.08%
- BEAM N/A
- EPS Growth
- AAMI 43.58
- BEAM N/A
- EPS
- AAMI 2.41
- BEAM N/A
- Revenue
- AAMI $538,200,000.00
- BEAM $60,272,000.00
- Revenue This Year
- AAMI $21.37
- BEAM N/A
- Revenue Next Year
- AAMI $16.37
- BEAM $18.20
- P/E Ratio
- AAMI $20.12
- BEAM N/A
- Revenue Growth
- AAMI 18.76
- BEAM N/A
- 52 Week Low
- AAMI $22.60
- BEAM $13.53
- 52 Week High
- AAMI $51.65
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- AAMI 56.01
- BEAM 65.37
- Support Level
- AAMI $47.88
- BEAM $19.57
- Resistance Level
- AAMI $49.31
- BEAM $21.59
- Average True Range (ATR)
- AAMI 1.73
- BEAM 1.47
- MACD
- AAMI -0.24
- BEAM 0.53
- Stochastic Oscillator
- AAMI 65.98
- BEAM 85.28
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.